Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (15408)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jul 7, 2019 (publication date) through Nov 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Jiang Y, Han QJ, Zhang J. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World J Gastroenterol 2019; 25(25): 3151-3167 [PMID: 31333308 DOI: 10.3748/wjg.v25.i25.3151] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v25/i25/3151.htm |
| Number | Citing Articles |
| 1 |
Firoz A. Dain Md Opo, Mohammed M. Rahman, Foysal Ahammad, Istiak Ahmed, Mohiuddin Ahmed Bhuiyan, Abdullah M. Asiri. Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anti-cancer agents targeting XIAP protein. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-83626-x
|
| 2 |
Qiuming Su, Lu Li, Xiaokai Li, Wang Li, Xibing Zhang, Yun Dong, Lei Han, Duo Wang, Jianghua Ran. CD97 serves as a novel biomarker of immune cell infiltration in hepatocellular carcinoma. World Journal of Surgical Oncology 2022; 20(1) doi: 10.1186/s12957-022-02829-2
|
| 3 |
Yuan Kong, Xiaoning Zhu, Xue Zhang, Zetian Li, Yue Yin, Jing Wang, Hong Jia. Traditional Chinese medicine combined with radiofrequency ablation improves primary liver cancer outcomes: A systematic review with meta-analysis. Heliyon 2023; 9(8): e18591 doi: 10.1016/j.heliyon.2023.e18591
|
| 4 |
Yaochong Tan, Xueting Dong, Donglin Zhuang, Buzi Cao, Hua Jiang, Qingnan He, Mingyi Zhao. Emerging roles and therapeutic potentials of ferroptosis: from the perspective of 11 human body organ systems. Molecular and Cellular Biochemistry 2023; 478(12): 2695 doi: 10.1007/s11010-023-04694-3
|
| 5 |
Alessandro Rizzo, Oronzo Brunetti, Giovanni Brandi. Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges. International Journal of Molecular Sciences 2024; 25(20): 11091 doi: 10.3390/ijms252011091
|
| 6 |
Maya S. Krishnan, Anand Rajan KD, Jangho Park, Vinodhini Arjunan, Fernando Jose Garcia Marques, Abel Bermudez, Olivia A. Girvan, Nam S. Hoang, Jun Yin, Mindie H. Nguyen, Nishita Kothary, Sharon Pitteri, Dean W. Felsher, Renumathy Dhanasekaran. Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers. Hepatology 2021; 73(6): 2342 doi: 10.1002/hep.31614
|
| 7 |
Tianbing Wang, Bang Chen, Tao Meng, Zhiqiang Liu, Wenyong Wu. Identification and immunoprofiling of key prognostic genes in the tumor microenvironment of hepatocellular carcinoma. Bioengineered 2021; 12(1): 1555 doi: 10.1080/21655979.2021.1918538
|
| 8 |
Ji-An You, Yuhan Gong, Yongzhe Wu, Libo Jin, Qingjia Chi, Da Sun. WGCNA, LASSO and SVM Algorithm Revealed RAC1 Correlated M0 Macrophage and the Risk Score to Predict the Survival of Hepatocellular Carcinoma Patients. Frontiers in Genetics 2022; 12 doi: 10.3389/fgene.2021.730920
|
| 9 |
Chun Chen, Yanqiu Gu, Rong Wang, Xinyi Chai, Shuya Jiang, Shaozhan Wang, Zhenyu Zhu, Xiaofei Chen, Yongfang Yuan. Comparative two-dimensional GPC3 overexpressing SK-Hep1 cell membrane chromatography /C18/ time-of-flight mass spectrometry for screening selective GPC3 inhibitor components from Scutellariae Radix. Journal of Chromatography B 2021; 1163: 122492 doi: 10.1016/j.jchromb.2020.122492
|
| 10 |
A. Yu. Goryainova, A. I. Stukan, R. A. Murashko, S. V. Sharov, O. I. Kirsanova, E. V. Lymar. Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitors. Meditsinskiy sovet = Medical Council 2021; (20): 84 doi: 10.21518/2079-701X-2021-20-84-93
|
| 11 |
Patrizia Leone, Antonio Giovanni Solimando, Rossella Fasano, Antonella Argentiero, Eleonora Malerba, Alessio Buonavoglia, Luigi Giovanni Lupo, Valli De Re, Nicola Silvestris, Vito Racanelli. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines 2021; 9(5): 532 doi: 10.3390/vaccines9050532
|
| 12 |
Hao Xu, Chen Xiong, Yuan Chen, Chi Zhang, Dousheng Bai. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma. Bioengineered 2021; 12(1): 2664 doi: 10.1080/21655979.2021.1938470
|
| 13 |
Jiaheng Xie, Liang Chen, Qingmei Sun, Haobo Li, Wei Wei, Dan Wu, Yiming Hu, Zhechen Zhu, Jingping Shi, Ming Wang. An immune subtype-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing analysis. Aging 2022; 14(7): 3276 doi: 10.18632/aging.204012
|
| 14 |
Wuyu Chen, Minghao Ruan, Minghao Zou, Fuchen Liu, Hui Liu. Clinical Significance of Non-Coding RNA Regulation of Programmed Cell Death in Hepatocellular Carcinoma. Cancers 2023; 15(16): 4187 doi: 10.3390/cancers15164187
|
| 15 |
Kimia Karimi, Sarah Mojtabavi, Pooya M. Tehrany, Melina Maghsodlou Nejad, Aryan Rezaee, Shahab Mohtashamian, Erfan Hamedi, Farnaz Yousefi, Farshid Salmani, Mohammad Arad Zandieh, Noushin Nabavi, Navid Rabiee, Yavuz Nuri Ertas, Shokooh Salimimoghadam, Mohsen Rashidi, Parham Rahmanian, Kiavash Hushmandi, Wei Yu. Chitosan-based nanoscale delivery systems in hepatocellular carcinoma: Versatile bio-platform with theranostic application. International Journal of Biological Macromolecules 2023; 242: 124935 doi: 10.1016/j.ijbiomac.2023.124935
|
| 16 |
Ghulam Mustafa, Shumaila Younas, Hafiza Salaha Mahrosh, Mohammed Fahad Albeshr, Eijaz Ahmed Bhat. Molecular Docking and Simulation-Binding Analysis of Plant Phytochemicals with the Hepatocellular Carcinoma Targets Epidermal Growth Factor Receptor and Caspase-9. Molecules 2023; 28(8): 3583 doi: 10.3390/molecules28083583
|
| 17 |
Baohui Zhang, Bufu Tang, Jiarui Lv, Jianyao Gao, Ling Qin. Systematic analyses to explore immune gene sets-based signature in hepatocellular carcinoma, in which IGF2BP3 contributes to tumor progression. Clinical Immunology 2022; 241: 109073 doi: 10.1016/j.clim.2022.109073
|
| 18 |
Liliang Wei, Qiuqiong Lv, Qiong Wang, Yibo Zhu, Feng Ding. Potential molecular mechanisms of Huangqin Tang for liver cancer treatment by network pharmacology and molecular dynamics simulations. Computer Methods in Biomechanics and Biomedical Engineering 2024; : 1 doi: 10.1080/10255842.2024.2353641
|
| 19 |
Xinchen Tian, Tinghao Yan, Fen Liu, Qingbin Liu, Jing Zhao, Huabao Xiong, Shulong Jiang. Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.991052
|
| 20 |
Xueyin Zhou, Jiasheng Cao, Win Topatana, Tianao Xie, Tianen Chen, Jiahao Hu, Shijie Li, Sarun Juengpanic, Ziyi Lu, Bin Zhang, Kaitai Wang, Xu Feng, Jiliang Shen, Mingyu Chen. Evaluation of PD-L1 as a Biomarker for Immunotherapy for Hepatocellular Carcinoma: Systematic Review and Meta-Analysis. Immunotherapy 2023; 15(5): 353 doi: 10.2217/imt-2022-0168
|
| 21 |
Wei Zhang, Miao Zeng, Yisheng Li, Li Yu. Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies. Biomarker Research 2024; 12(1) doi: 10.1186/s40364-024-00617-6
|
| 22 |
Muhammed Mehdi Üremiş, Nuray Üremiş, Yusuf Türköz. Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways. Steroids 2023; 198: 109261 doi: 10.1016/j.steroids.2023.109261
|
| 23 |
Lin Sun, Luwen Mu, Jing Zhou, Wenjie Tang, Linqi Zhang, Sidong Xie, Jingbiao Chen, Jin Wang. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunology, Immunotherapy 2022; 71(1): 25 doi: 10.1007/s00262-021-02957-w
|
| 24 |
Awang Danzeng, Ling Guo, Zhen-hua Yang, Zheng-wei He, Cheng-long Zeng, Pingcuo Ciren, Run-hu Lan, Xue-wei Jiang, Chao Wang, Bin-hao Zhang. Postoperative lenvatinib + PD-1 blockade reduces early tumor recurrence in hepatocellular carcinoma with microvascular invasion (Barcelona Clinic Liver Cancer stage 0 or A): a propensity score matching analysis. Journal of Gastrointestinal Surgery 2024; 28(7): 1104 doi: 10.1016/j.gassur.2024.05.001
|
| 25 |
Ola M. S. Khedr, Sawsan M. El-Sonbaty, Fatma S. M. Moawed, Eman I. Kandil, Basma E. Abdel-Maksoud. Lactobacillus acidophilus ATCC 4356 Exopolysaccharides Suppresses Mediators of Inflammation through the Inhibition of TLR2/STAT-3/P38-MAPK Pathway in DEN-Induced Hepatocarcinogenesis in Rats. Nutrition and Cancer 2022; 74(3): 1037 doi: 10.1080/01635581.2021.1934490
|
| 26 |
Mihai Ceausu, Bogdan Socea, Dragos Serban, Cătălin Smarandache, Dragoş Predescu, Nicolae Bacalbaşa, Iulian Slavu, Adrian Tulin, Lucian Alecu, Zenaida Ceauşu. Heterogeneity of antigenic constellation in human hepatocellular carcinoma. Experimental and Therapeutic Medicine 2021; 21(3) doi: 10.3892/etm.2021.9701
|
| 27 |
Jing Liu, Tongyu Liu, Chuanhao Zhang, Jiabei He, Dong Zhou, Zhe Wang, Ruoyu Wang. EIF2S2 is a novel independent prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Frontiers in Genetics 2022; 13 doi: 10.3389/fgene.2022.992343
|
| 28 |
Chaohui Liu, Jiansheng Pan, Hongyu Liu, Rongkai Lin, Yijie Chen, Chenghua Zhang. Daphnetin inhibits the survival of hepatocellular carcinoma cells through regulating Wnt/β‐catenin signaling pathway. Drug Development Research 2022; 83(4): 952 doi: 10.1002/ddr.21920
|
| 29 |
Xu-Sheng Zhang, Hong-Cai Zhou, Peng Wei, Long Chen, Wei-Hu Ma, Lin Ding, Shi-Cai Liang, Ben-Dong Chen. Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses. World Journal of Gastrointestinal Oncology 2023; 15(12): 2138-2149 doi: 10.4251/wjgo.v15.i12.2138
Abstract(344) |
Core Tip(359) |
Full Article(HTML)(1376)
|
Full Article with Cover (PDF)-10469K(58)
|
Full Article (Word)-3354K(24)
|
Audio-263K(6)
|
Peer-Review Report-209K(43)
|
Answering Reviewers-113K(40)
|
Full Article (PDF)-10227K(82)
|
Full Article (XML)-89K(41)
|
Times Cited (2)
|
Total Visits (4081)
|
Open
|
| 30 |
Yalei Zhao, Chen Xue, Zhongyang Xie, Xiaoxi Ouyang, Lanjuan Li. Comprehensive analysis of ubiquitin‐specific protease 1 reveals its importance in hepatocellular carcinoma. Cell Proliferation 2020; 53(10) doi: 10.1111/cpr.12908
|
| 31 |
Liang Sun, Zhengyi Wu, Cairong Dong, Shian Yu, He Huang, Zhendong Chen, Zhipeng Wu, Xiangbao Yin. Signature construction and molecular subtype identification based on immune-related genes for better prediction of prognosis in hepatocellular carcinoma. BMC Medical Genomics 2023; 16(1) doi: 10.1186/s12920-023-01558-z
|
| 32 |
Muhammed Mehdi Üremiş, Nuray Üremiş, Emir Tosun, Merve Durhan, Yılmaz Çiğremiş, Ahmet Baysar, Yusuf Türköz. Cucurbitacin D Inhibits the Proliferation of HepG2 Cells and Induces
Apoptosis by Modulating JAK/STAT3, PI3K/Akt/mTOR and MAPK Signaling
Pathways. Current Cancer Drug Targets 2022; 22(11): 931 doi: 10.2174/1568009622666220623141158
|
| 33 |
Said Abu-Alkhair Mohamed, Yasser Mohamed Eldowik. The role of glypican 3, arginase 1, and CD34 in differentiation between benign and malignant primary hepatic lesions. Al-Azhar Assiut Medical Journal 2022; 20(3): 239 doi: 10.4103/azmj.azmj_105_21
|
| 34 |
Janis M. Lapsley, Vincent Wavreille, Sabrina Barry, Josephine A. Dornbusch, Carolyn Chen, Haley Leeper, Judith Bertran, Diane Scavelli, Julius M. Liptak, Chris Wood, Shelly Shamir, Claire Rosenbaum, Vincenzo Montinaro, Brandan Wustefeld‐Janssens, Allyson Sterman, Colin Chik, Ameet Singh, Josh Collins, Laura E. Selmic. Risk factors and outcome in dogs with recurrent massive hepatocellular carcinoma: A Veterinary Society of Surgical Oncology case–control study. Veterinary and Comparative Oncology 2022; 20(3): 697 doi: 10.1111/vco.12824
|
| 35 |
Yakun Wang, Lei Yang, Xichen Dong, Xin Yang, Xinxue Zhang, Zhe Liu, Xin Zhao, Tao Wen, Hui Yu. Overexpression of NNT-AS1 Activates TGF-β Signaling to Decrease Tumor CD4 Lymphocyte Infiltration in Hepatocellular Carcinoma. BioMed Research International 2020; 2020: 1 doi: 10.1155/2020/8216541
|
| 36 |
Jing Li, Minling Lv, Qi Huang, Rui Hu, Xin Zhong, Xinfeng Sun, Wenxing Feng, Zhiyi Han, MengQing Ma, Wei Zhang, Xiaozhou Zhou. FAT4 expression in peripheral blood mononuclear cells is associated with prognosis and immune cell infiltration in hepatocellular carcinoma. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-42560-w
|
| 37 |
Pu Wu, Jinyuan Shi, Wei Sun, Hao Zhang. The prognostic value of plasma complement factor B (CFB) in thyroid carcinoma. Bioengineered 2021; 12(2): 12854 doi: 10.1080/21655979.2021.2005745
|
| 38 |
Kun Zhao, Jie Gao, Jihua Shi, Chengcheng Shi, Chun Pang, Jie Li, Wenzhi Guo, Shuijun Zhang. FXR1 promotes proliferation, invasion and migration of hepatocellular carcinoma in vitro and in vivo. Oncology Letters 2022; 25(1) doi: 10.3892/ol.2022.13608
|
| 39 |
Runjie Song, Shuoqian Ma, Jiajia Xu, Xin Ren, Peilan Guo, Huijiao Liu, Peng Li, Fan Yin, Mei Liu, Qiang Wang, Lei Yu, Jiali Liu, Binwei Duan, Nafis A. Rahman, Sławomir Wołczyński, Guangming Li, Xiangdong Li. A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR. Molecular Cancer 2023; 22(1) doi: 10.1186/s12943-023-01719-9
|
| 40 |
X Liu, H Ren, H Guo, W Wang, N Zhao. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma. Clinical and Experimental Immunology 2021; 203(2): 219 doi: 10.1111/cei.13535
|
| 41 |
Mengqi Xin. Research and Treatment Progress of Capmatinib in Hepatocellular Carcinoma. Highlights in Science, Engineering and Technology 2022; 8: 576 doi: 10.54097/hset.v8i.1217
|
| 42 |
Di Ma, Juan Wang, Lu Liu, Meiqi Chen, Zhiyong Wang. Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-07447-3
|
| 43 |
Jia-Ren Wang, Rui-Ning Li, Chao-Yi Huang, Chang Hong, Qi-Mei Li, Lin Zeng, Jing-Zhe He, Cheng-Yi Hu, Hao Cui, Li Liu, Lu-Shan Xiao. Impact of antibiotics on the efficacy of immune checkpoint inhibitors in the treatment of primary liver cancer. Liver Research 2022; 6(3): 175 doi: 10.1016/j.livres.2022.05.004
|
| 44 |
Wenxiong Xu, Yanlin Huang, Yongyu Mei, Yeqiong Zhang, Qiumin Luo, Shu Zhu, Liang Peng, Zhiliang Gao, Ying Liu, Jianguo Li. High Expression of POGK Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma. Current Oncology 2022; 29(11): 8650 doi: 10.3390/curroncol29110682
|
| 45 |
Hongzhi Zhao, Liang Zhao, Lin Wu, Sheng Hu, Yangmei Huang, Wei Zhao. Hydrogen sulfide suppresses H2O2-induced proliferation and migration of HepG2 cells through Wnt/β-catenin signaling pathway. Medical Oncology 2023; 40(8) doi: 10.1007/s12032-023-02091-w
|
| 46 |
Yuting Gao, Yi Gong, Yiwei Liu, Yu Xue, Kangning Zheng, Yinglin Guo, Liyuan Hao, Qing Peng, Xinli Shi. Integrated analysis of transcriptomics and metabolomics in human hepatocellular carcinoma HepG2215 cells after YAP1 knockdown. Acta Histochemica 2023; 125(1): 151987 doi: 10.1016/j.acthis.2022.151987
|
| 47 |
Yifei Dai, Weijie Qiang, Kequan Lin, Yu Gui, Xun Lan, Dong Wang. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma. Cancer Immunology, Immunotherapy 2021; 70(4): 967 doi: 10.1007/s00262-020-02743-0
|
| 48 |
Olayinka Fisayo Onifade, Oluseyi Adeboye Akinloye, Oluwatosin A. Dosumu, Abdul Lateef Aderemi Shotuyo. In silico and in vivo anti-angiogenic validation on ethanolic extract of Curcuma longa and curcumin compound in hepatocellular carcinoma through mitogen activated protein kinase expression in male and female wistar rats. Food and Chemical Toxicology 2023; 182: 114096 doi: 10.1016/j.fct.2023.114096
|
| 49 |
Xuefeng Kan, Guanhui Zhou, Feng Zhang, Hongxiu Ji, David S Shin, Wayne Monsky, Chuansheng Zheng, Xiaoming Yang. Enhanced efficacy of direct immunochemotherapy for hepatic cancer with image-guided intratumoral radiofrequency hyperthermia. Journal for ImmunoTherapy of Cancer 2022; 10(11): e005619 doi: 10.1136/jitc-2022-005619
|
| 50 |
Lanqian Su, Huanyu Luo, Yalan Yan, Zhongqiu Yang, Jiaan Lu, Danqi Xu, Linjuan Du, Jie Liu, Guanhu Yang, Hao Chi. Exploiting gender-based biomarkers and drug targets: advancing personalized therapeutic strategies in hepatocellular carcinoma. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1433540
|
| 51 |
Wei Wang, Fan Pan, Xinrong Lin, Jiakai Yuan, Chunyu Tao, Rui Wang. Ferroptosis-Related Hub Genes in Hepatocellular Carcinoma: Prognostic Signature, Immune-Related, and Drug Resistance Analysis. Frontiers in Genetics 2022; 13 doi: 10.3389/fgene.2022.907331
|
| 52 |
Rizwan Qureshi, Bin Zou, Tanvir Alam, Jia Wu, Victor H. F. Lee, Hong Yan. Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects. IEEE/ACM Transactions on Computational Biology and Bioinformatics 2023; 20(1): 238 doi: 10.1109/TCBB.2022.3141697
|
| 53 |
Wenge Dong, Yangyang Xie, Hai Huang. Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.884777
|
| 54 |
Yi Huang, Zhou Yu, Min Zheng, Xiaohong Yang, Honglan Huang, Lijin Zhao. Methylation‑associated inactivation of JPH3 and its effect on prognosis and cell biological function in HCC. Molecular Medicine Reports 2022; 25(4) doi: 10.3892/mmr.2022.12640
|
| 55 |
Jinlong Liang, Jingyi Wang, Jinshui Zeng, Zhibo Bai, Zhiyuan Zheng, Yue Zheng, Fengqi Jiang, Di Wu, Fu Wang. The Landscape of Early Growth Response Family Members 1-4 in Hepatocellular Carcinoma: Their Biological Roles and Diagnostic Utility. Disease Markers 2022; 2022: 1 doi: 10.1155/2022/3144742
|
| 56 |
Liyang Jia, Yanan Gao, Yaowu He, John D. Hooper, Pengyuan Yang. HBV induced hepatocellular carcinoma and related potential immunotherapy. Pharmacological Research 2020; 159: 104992 doi: 10.1016/j.phrs.2020.104992
|
| 57 |
Haichuan Wang, Yu Zhang, Li Yan, Qiang Lv, Jie Lu, Bei Yun. Analysis of TRIM27 prognosis value and immune infiltrates in hepatocellular carcinoma. International Journal of Immunopathology and Pharmacology 2022; 36 doi: 10.1177/03946320221132986
|
| 58 |
露 梅. Clinical Research Progress on Modified Chaishao Liujunzi Decoction in the Treatment of Hepatic Diseases. Traditional Chinese Medicine 2024; 13(04): 680 doi: 10.12677/tcm.2024.134106
|
| 59 |
Hao Liang, Mingxing Xu, Zhiyong Xiong, Kunpeng Hu, Jiarui Yang, Mingbo Cao, Zhaozhong Zhong, Zhicheng Yao, Meihai Deng, Bo Liu. Identification of miRNAs as diagnostic and prognostic markers in hepatocellular carcinoma. Aging 2021; 13(4): 6115 doi: 10.18632/aging.202606
|
| 60 |
Romelia Pop, Dragoș Hodor, Cornel Cătoi, Teodora Mocan, Lucian Mocan, Alexandru-Flaviu Tăbăran. Unveiling the Role of Concanavalin A in a Rodent Model of Chemical-Induced Hepatocellular Carcinoma: A Promising Guide in Understanding Liver Cancer Development. Targets 2024; 2(1): 52 doi: 10.3390/targets2010003
|
| 61 |
Kai Tan, Kunlei Wang, Anbang Zhao, Zhicheng Liu, Wenjing Song, Qian Cheng, Xinyin Li, Zhinan Chen, Yufeng Yuan, Zhiyong Yang. Meiotic nuclear divisions 1 promotes proliferation and metastasis in hepatocellular carcinoma and is a potential diagnostic and therapeutic target gene. Medical Oncology 2022; 40(1) doi: 10.1007/s12032-022-01875-w
|
| 62 |
Liwei Sun, Xuelong Xu, Fanguang Meng, Qian Liu, Hankang Wang, Xiaodong Li, Guijie Li, Feng Chen. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.980214
|
| 63 |
Xinyue Tu, Jie Zhang, Minjun Li, Fei Lu, Ting Wang, Wenfeng Gong, Bangde Xiang. Development and Validation of a Prediction Model for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients Receiving Postoperative Adjuvant Transarterial Chemoembolization. Journal of Hepatocellular Carcinoma 2023; : 1881 doi: 10.2147/JHC.S422565
|
| 64 |
Haiyan Zhang, Shanshan Pei, Jiaxuan Li, Jiajie Zhu, Hongyu Li, Guangshang Wu, Ruiqi Weng, Ruyi Chen, Zhongbiao Fang, Jingbo Sun, Keda Chen. Insights about exosomal circular RNAs as novel biomarkers and therapeutic targets for hepatocellular carcinoma. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1466424
|
| 65 |
Mehrdad Hashemi, Pouria Daneii, Mahya Asadalizadeh, Kiana Tabari, Arash Matinahmadi, Seyed Shahabadin Bidoki, Yasamin Sadat Mousavi Motlagh, Ali Moghadas Jafari, Amin Ghorbani, Amir Dehghanpour, Noushin Nabavi, Shing Cheng Tan, Mohsen Rashidi, Afshin Taheriazam, Maliheh Entezari, Mohammad Ali Sheikh Beig Goharrizi. Epigenetic regulation of hepatocellular carcinoma progression: MicroRNAs as therapeutic, diagnostic and prognostic factors. The International Journal of Biochemistry & Cell Biology 2024; 170: 106566 doi: 10.1016/j.biocel.2024.106566
|
| 66 |
Lei Cao, Yu-Qin Zhu, Zhi-Xian Wu, Gao-Xiong Wang, Hong-Wei Cheng. Engineering nanotheranostic strategies for liver cancer. World Journal of Gastrointestinal Oncology 2021; 13(10): 1213-1228 doi: 10.4251/wjgo.v13.i10.1213
|
| 67 |
Xi Wang, Xuchen Zhang. Hepatocellular adenoma: Where are we now?. World Journal of Gastroenterology 2022; 28(14): 1384-1393 doi: 10.3748/wjg.v28.i14.1384
|
| 68 |
Xin Li, Jiahua Xu, Xiaoqiang Gu, Ling Chen, Qing Wu, Hongwei Li, Haoran Bai, Jinzu Yang, Jianxin Qian. Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.740790
|
| 69 |
Xiaobin Fei, Songbai Liu, Peng Liu, Xing Wang, Changhao Zhu, Junyi Hou, Junzhe Cai, Yaozhen Pan. Identification and validation of a potential key gene SGOL1 for poor prognosis in hepatocellular carcinoma based on a bioinformatics approach. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1043161
|
| 70 |
Dan Chen, Xiaoting Li, Hui Li, Kai Wang, Xianghua Tian, Jimei Wang. Identification of Immune-Related Prognostic mRNA and lncRNA in Patients with Hepatocellular Carcinoma. Journal of Oncology 2022; 2022: 1 doi: 10.1155/2022/5313149
|
| 71 |
Youpeng Wang, Yeni Yang, Ziyin Zhao, Hongfa Sun, Dingan Luo, Lakshmi Huttad, Bingyuan Zhang, Bing Han. A new nomogram model for prognosis of hepatocellular carcinoma based on novel gene signature that regulates cross-talk between immune and tumor cells. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09465-9
|
| 72 |
Nesil Yalman. LMCD1 antisense RNA 1 is a newly identified long noncoding RNA. Anti-Cancer Drugs 2022; 33(1): 1 doi: 10.1097/CAD.0000000000001124
|
| 73 |
Subin Heo, Bohyun Kim, So Yeon Kim, Hyo Jeong Kang, In Hye Song, Sung Hak Lee, Jimi Huh, Seokhwi Kim, Seunghee Baek, Seung Soo Lee, Sang Hyun Choi, Jong Keon Jang, Seong Ho Park. A Multicenter Study on Hepatocellular Adenomas in Korea: Clinicopathological and Imaging Features With an Emphasis on β‐Catenin Mutated Subtype. Liver International 2024; doi: 10.1111/liv.16155
|
| 74 |
Ling Zhang, Tao Wang, Jieqiong Song, Feng Guo. Effect of RhD and RhE sample phenotypic blood transfusion on the prognosis of hepatocellular carcinoma. Medicine 2023; 102(49): e36369 doi: 10.1097/MD.0000000000036369
|
| 75 |
Kun He, Mengyi Xie, Weifeng Hong, Yonghe Li, Yaolin Yin, Xiaojin Gao, Yi He, Yu Chen, Chuan You, Jingdong Li. CENPL accelerates cell proliferation, cell cycle, apoptosis, and glycolysis via the MEK1/2-ERK1/2 pathway in hepatocellular carcinoma. The International Journal of Biochemistry & Cell Biology 2024; 166: 106481 doi: 10.1016/j.biocel.2023.106481
|
| 76 |
Raheleh Roudi, Alberto D'Angelo, Marianna Sirico, Navid Sobhani. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. International Immunopharmacology 2021; 101: 108322 doi: 10.1016/j.intimp.2021.108322
|
| 77 |
Qiuming Su, Wang Li, Xibing Zhang, Ruichao Wu, Kepu Zheng, Tao Zhou, Yun Dong, Yutao He, Duo Wang, Jianghua Ran. Integrated Bioinformatics Analysis for the Screening of Hub Genes and
Therapeutic Drugs in Hepatocellular Carcinoma. Current Pharmaceutical Biotechnology 2023; 24(8): 1035 doi: 10.2174/1389201023666220628113452
|
| 78 |
Nuray Üremiş, Muhammed Mehdi Üremiş, Yılmaz Çiğremiş, Emir Tosun, Ahmet Baysar, Yusuf Türköz.
Cucurbitacin I exhibits anticancer efficacy through induction of apoptosis and modulation of
JAK
/
STAT3
,
MAPK
/
ERK
, and
AKT
/
mTOR
signaling pathways in
HepG2
cell line
. Journal of Food Biochemistry 2022; 46(10) doi: 10.1111/jfbc.14333
|
| 79 |
Zhou Lu, Ronghua Liu, Yining Wang, Mengxia Jiao, Zhongchen Li, Zhiqiang Wang, Cheng Huang, Guoming Shi, Aiwu Ke, Luman Wang, Ying Fu, Jie Xia, Haoyu Wen, Jian Zhou, Xiaoying Wang, Dan Ye, Jia Fan, Yiwei Chu, Jiabin Cai. Ten‐eleven translocation‐2 inactivation restrains IL‐10‐producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma. Hepatology 2023; 77(3): 745 doi: 10.1002/hep.32442
|
| 80 |
Yu Teng, Jianrong Xu, Yaoqun Wang, Ningyuan Wen, Bei Li, Hui Ye. Combining a glycolysis‑related prognostic model based on scRNA‑Seq with experimental verification identifies ZFP41 as a potential prognostic biomarker for HCC. Molecular Medicine Reports 2024; 29(5) doi: 10.3892/mmr.2024.13203
|
| 81 |
Yagmur Azbazdar, Mustafa Karabicici, Esra Erdal, Gunes Ozhan. Regulation of Wnt Signaling Pathways at the Plasma Membrane and Their Misregulation in Cancer. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.631623
|
| 82 |
Camille Marcantei, Alexis Couret, James King, Simon Mazeaud, Abergel Armand, Gaël Ennequin. Effects of Exercise Training on Muscle Mass and Physical Function in Patients with Hepatocellular Carcinoma After Diagnosis: A Systematic Review. Digestive Diseases and Sciences 2024; 69(7): 2667 doi: 10.1007/s10620-024-08441-6
|
| 83 |
Luyun Yuan, Jinkai Feng, Yuqing Zhang, Chongde Lu, Liu Xu, Chao Liang, Zonghan Liu, Feifei Mao, Yanjun Xiang, Weijun Wang, Kang Wang, Shuqun Cheng. Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter cohort study. European Journal of Surgical Oncology 2023; 49(7): 1226 doi: 10.1016/j.ejso.2023.01.020
|
| 84 |
Li Peng, Qi Yan, Zhaolin Chen, Ying Hu, Yuansong Sun, Yu Miao, Yincui Wu, Yan Yao, Liangsong Tao, Fei Chen, He Li, Tao Xu. Research progress on the role of cholesterol in hepatocellular carcinoma. European Journal of Pharmacology 2023; 938: 175410 doi: 10.1016/j.ejphar.2022.175410
|